Mistakes in DNA repair can lead to cancer. But they also present opportunities for treatment. Today at the San Antonio Breast Cancer Symposium, MSK Radiation Oncology Chair Simon Powell discusses new ...

Homologous recombination (HR) functions as a major pathway in the repair of DNA double-strand breaks (DSBs) and genome replication damage. DSBs are major pathological DNA structures in dividing cells, ...

In mammals, 17 PARP family members have been discovered, and only 6 of these synthesize poly ADP-ribose (pADPr). PARP1, PARP2, and PARP3 have roles in DNA repair. PARP1 binds to DNA that has suffered ...

Although the first foray into the clinic for PARP inhibitors was in combination with DNA-damaging chemotherapy, clinical development was limited by the more-than-additive toxicity, in particular ...

An educational session helps oncologists understand the decision-making process for selecting treatments for recurrent ovarian cancer. New therapeutic options—with more on the horizon—offer ...

A breast cancer treatment for women with a form of the disease called “triple-negative” has been shown to increase survival time. The study showed that adding a type of medication called a PARP ...

Studies by a Dana-Farber Cancer Institute (DFCI)-led research team suggest that disabling immune suppression mediated by a specific type of macrophage may boost the effectiveness of poly ADP ribose ...

Looking for ways to halt the uncontrolled growth of cancer cells, scientists at Johns Hopkins have found that a new class of drugs, called PARP inhibitors, may block the ability of pre-leukemic cells ...

The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...

The Phase 3 AMPLITUDE trial led by UCL found that adding the PARP inhibitor niraparib to standard hormone therapy may slow ...

Big players have been carving out a niche in the small but thriving field of poly(ADP-ribose) polymerase (PARP) inhibitors, as long-awaited data roll out that validate the experimental approach. In ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first precision medicine combo for patients with BRCA2-mutated metasta | Akeega, a ...